

Review

Not peer-reviewed version

Exploring the Significance of Gut Microbiota in Cardiovascular Health

[Shamima Akter](#) , [Mayank Choubey](#) , Shahida Arbee , [Mohammad Mohabbulla Mohib](#) , [Munichandra B. Tirumalasetty](#) , Naofel Minhaz , Asif Akhtar , Nadera Naquib Bismee , [Mohammad Sarif Mohiuddin](#) *

Posted Date: 30 August 2023

doi: 10.20944/preprints202308.1970.v1

Keywords: Cardiovascular health; gut microbiota; microbiome; dysbiosis, atherosclerosis



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

Exploring the Significance of Gut Microbiota in Cardiovascular Health

Shamima Akter ¹, Mayank Choubey ², Shahida Arbee ³, Mohammad Mohabbulla Mohib ⁴,
Munichandra Babu Tirumalasetty ², Naofel Minhaz ⁵, Asif Akhtar ², Nadera Naquib Bismee ⁶ and
Mohammad Sarif Mohiuddin ^{2,*}

¹ Department of Internal Medicine, St. Francis—Emory Healthcare, 2122 Manchester Expressway, Columbus, GA 31904, USA

² Department of Foundations of Medicine, NYU Long Island School of Medicine, 101 Mineola Blvd, Mineola, NY 11501, USA.

³ Institute for Molecular Medicine, Aichi Medical University, 1-Yazako, Karimata, Aichi, Nagakute 480-1103, Japan

⁴ Julius Bernstein Institute of Physiology, Medical School, Martin Luther University of Halle-Wittenberg, Magdeburger Straße 6, 06112 Halle, Germany.

⁵ Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University Hospital, Dhaka 1000, Bangladesh

⁶ Department of Medicine, Uttara Adhunik Medical College Hospital, Dhaka, Bangladesh

* Correspondence: sharif@gmail.com; Tel.: +1-901-336-8634

Abstract: Cardiovascular disease (CVD), comprising heart and blood vessel disorders, persists as the foremost contributor to global morbidity and mortality. In modern times, the intricate composition of gut microbiota has garnered significant focus, particularly for its varying impact on diverse ailments. Perturbations in gut microbiota and consequent dysbiosis have demonstrated connections with the advancement and origin of CVD, including conditions like atherosclerosis, hypertension, and heart failure. This comprehensive review delves into the pivotal role of gut microbiota in maintaining cardiovascular well-being.

Keywords: cardiovascular health; gut microbiota; microbiome; dysbiosis; atherosclerosis

1. Introduction

The gut microbiota, a diverse and dynamic collection of microorganisms found in the human GI tract, has a significant impact on the host both in times of homeostasis and disease. The human body is home to trillions of microorganisms, which work together to create a dynamic ecosystem both within and outside of the body [1]. This ecosystem's alterations and interactions have an impact on human health and sickness [2]. This complex ecosystem, which is made up of a wide variety of bacteria, viruses, fungus, and other microbes, was originally only marginally related to digestion. The gut microbiota, sometimes referred to as the "forgotten organ," is now understood to be a dynamic colony of bacteria that is essential to preserving our general health [3]. From the modulation of neuronal transmission to the digestion of complex polysaccharides, the gut microbiota is crucial to a wide range of physiological activities. It has gained increasing attention in recent years due to its link to a wide range of diseases, including Type 1 diabetes [4,5], reproductive health [6–10], autoimmune disease rheumatoid arthritis, inflammatory bowel disease [11], metabolic disorders like diabetes and its complications, cardiovascular disease (CVD), obesity, cancer [12], and sexual disorders [13–16], as well as neurodevelopmental disorders like autism and neurodegenerative diseases like Alzheimer's disease.

Cardiovascular diseases (CVD) leading cause of death in 2015, followed by cancer fatalities (595,930), making it one of the two biggest causes of death in the US since 1975 (633,842 deaths, or 1 in every 4 deaths) [17]. According to the World Health Organization (WHO), CVD is also the leading

cause of death worldwide, accounting for 17.7 million fatalities in 2015. With estimated indirect costs of \$237 billion annually and a projected increase to \$368 billion by 2035, CVD is considered the most expensive disease, even more so than diabetes and Alzheimer's disease [18,19].

While we've long known that the gut plays an important role in digestion and nutrient absorption, the scope of its influence has grown substantially. Scientific advances in microbiology and health studies have revealed a surprising link between the gut microbiota and the cardiovascular system. What was long thought to be two distinct domains – the gut and the heart – is now acknowledged to be a dynamic interplay of signals, chemicals, and influences that can have a considerable impact on our cardiovascular health. In this article we will encompass the various facets such as intricate mechanisms that link gut health to inflammation and blood vessel function, how gut microbes can influence blood pressure regulation and lipid metabolism[20,21]. We'll also explore how the gut microbiota affects metabolic health and how it contributes to the onset of atherosclerosis, the condition that is the root of CVD[22].

2. Diversity and Composition the Gut Microbiota

Around 100-trillion microorganisms (bacteria, fungi, viruses, protozoa, and viruses) are found in the human gut. The microbiome has nearly 3 million genes that produce thousands of metabolites that have an impact on human health, compared to the 23,000 genes that make up the human genome [1]. A number of variables, including as food, demographics, medication use, health status, and environmental elements influencing the gut environment, have an impact on the composition and metabolism of adult gut microbial populations[23–25]. The Human Microbiome Project Consortium found that 208 donors represented 226 bacterial species in the total fecal microbiota richness [3,26].

3. Emerging Insights: Gut Microbiota and Cardiovascular Health:

3.1. *The Inflammation: Unveiling the Role of Gut Health in Cardiovascular Diseases*

Inflammation, often act as defense mechanism of the body, known as double-edged sword. Chronic inflammation can become a silent enemy, wreaking havoc on our health and laying the groundwork for a number of chronic diseases, including cardiovascular disorders, even while it is essential for warding off infections and encouraging healing. Our gut health is a surprise factor in this inflammatory cascade, according to recent studies. Inflammation is a key mechanism of cardiovascular diseases. It is an integral part of atherosclerosis and a major contributor to the occurrence of cardiovascular events. Inflammation has been observed that patients with heart failure have higher levels of inflammatory cytokines [27]. Redox and inflammatory signals can affect permeability pathways, and this is shown in CVD [28]. Changes in the composition of gut microbiota known as Gut dysbiosis (Figure 1) can lead to a decrease in hazardous bacteria (including Collinsella, Proteobacteria, and Enterobacteriaceae) and an increase in helpful bacteria (Bacteroidetes and Firmicutes). High quantities of lipopolysaccharide (LPS) are produced in the dysbiotic gut by Gram-negative pathogens such Escherichia coli, which then cause atherogenesis and systemic inflammation (endotoxemia) [29]. The intestinal mucosal epithelial barrier, which guards the internal milieu from the hostile external environment, is kept in place by the development of tight junctions (TJs, a complex made of intramembranous proteins, occludin, and several molecules from the claudin family of proteins), which spread between the epithelial cells and create a semi-permeable seal [30]. In a sick state, this barrier ceases to serve as a barrier, increasing intestinal permeability, particularly to LPS generated locally by the gut bacteria. Prior until recently, it was believed that certain pathological conditions were the source of leaky gut, however a number of studies have suggested that the pathological illnesses are not the cause of leaky gut [31]. One of the main factors leading to arterial plaque and blockages can be inflammation from leaky gut [32]. In actuality, patients with heart disease exhibit higher rates of leaky gut than people without heart disease. On the artery walls, inflammation causes lesions. With cholesterol, the body "bandages" them, and the result is plaque. Atherosclerosis is the term for this process [33,34].




Figure 1. Mechanism of atherosclerosis due to gut dysbiosis.

Plaque in the arteries is encouraged by inflammation, but it is also less stable due to inflammation. To prevent heart attacks, plaque stability is essential [35]. Plaque ruptures, causing it to become loose and clog the artery, depriving the heart of blood and resulting in a heart attack. It is well known that a leaky gut is a major contributor to the chronic inflammation that can inflame and clog your arteries [36].

3.2. Microbial Architects of Cholesterol: Gut Microbiota's Influence on Lipid Metabolism

An international investigation found that of all modifiable risk factors for cardiovascular disease, elevated serum cholesterol levels were linked to the highest attributable risk for developing CVD, particularly ischemic heart disease [37]. Studies suggest that high serum total cholesterol (TC) is the primary factor causing coronary atherosclerosis, and it is widely known that elevated TC is linked to an increased risk of CVD [38]. Numerous epidemiological and interventional investigations have determined that LDL-C is the primary risk factor for CVD since it is a crucial factor in the development of atherosclerosis [39,40].

A sizable portion of patients cannot stop the progression of atherosclerosis despite effective cholesterol-modulating therapy (such as statins). It is well known that bile acids, which are the primary form in which cholesterol is excreted from the body by the liver [41]. The liver converts cholesterol into the amphipathic molecules known as bile acids. For the breakdown of hepatic cholesterol, bile acid production is a key route. It is vital for the biliary secretion of free cholesterol, endogenous metabolites, and xenobiotics that bile flow is produced through bile acid production. Biological deodorants called bile acids make it easier for lipids and fat-soluble vitamins to be

absorbed by the digestive tract. Bile acids may be crucial metabolic regulators of lipid, glucose, and energy homeostasis, according to recent studies [42].

Gut microbiota plays a vital role in Deconjugation, dehydroxylation, and reconjugation of these molecules result in the biotransformation of BA [43]. The possibility that gut microorganisms could affect cholesterol levels was emphasized by a ground-breaking study that appeared in the journal *Nature*. In the study, scientists gave mice with altered cholesterol metabolism gut bacteria from human donors. The results were startling; animals given microbiota from donors with high cholesterol had higher levels of LDL cholesterol, indicating a clear link between the gut microbiota and cholesterol management [44]. This expanding knowledge of the gut microbiota's function in lipid metabolism is changing how we think about cholesterol control and opening up new treatment possibilities.

A group of researchers from Broad Institute of MIT, revealed the function of the gut microbiota in bile acid metabolism, a crucial aspect of controlling cholesterol. A probable mechanism by which these bacteria may lower host serum cholesterol levels is that the presence of coprostanol-forming bacteria in stool samples is related with lower levels of fecal cholesterol. This observation emphasizes not just the sophisticated enzymatic capabilities of gut bacteria, but also their ability to influence host cholesterol pathways [45].

Wang and colleague observed that, the gut microbiota modulates mammalian lipid absorption, metabolism, and storage. The study found that different microbial populations can considerably influence the absorption of dietary lipids and cholesterol, hence influencing their incorporation into lipoproteins. Microbiota alters intestinal lipid metabolism in mice by suppressing the expression of *Snhg9* (small nucleolar RNA host gene 9) in small intestinal epithelial cells [46].

A study published in the *European Heart Journal* highlighted the potential of probiotics in modifying cholesterol metabolism. The study focused on *Lactobacillus reuteri*, a probiotic strain, and found that it might lower LDL cholesterol levels in mice by transforming cholesterol into a less absorbable form. This work demonstrates the potential of using probiotics to alter lipid profiles, yet it calls for additional clinical studies using human participants [47].

3.3. Gut microbiota obesity, a major risk factor for heart disease

Obesity raises the risk of cardiovascular disease (CVD), especially heart failure (HF) and coronary heart disease (CHD). Changes in body composition that might impact hemodynamics and change the anatomy of the heart are among the ways through which obesity raises CVD risk [48]. Adipose tissue produced pro-inflammatory cytokines can cause cardiovascular dysfunction and encourage the development of atherosclerotic plaques [49].

A Scientific Statement from the American Heart Association in 2021 discussed Independent of other cardiovascular risk factors, obesity increases the risk of developing cardiovascular disease and dying from it [49,50].

The gut microbiota exerts direct effects on the digestion, absorption and metabolism of food. Furthermore, the gut microbiota shows a miscellany of protective, structural and metabolic effects both on the intestinal milieu and peripheral tissues, thus affecting body weight by modulating metabolism, appetite, bile acid metabolism, and the hormonal and immune systems.

Investigations into the connection between the microbiota and body weight management have not revealed a clear causal relationship or association between these two factors [51], but it is believed that the composition of bacterial species varies depending on whether or not obesity is present.

A metagenomic and biochemical analyses study by Turnbaugh et al, observed Obese people's microbiomes can extract more energy from their diet which results increase the total body fat [52]. A group of researcher from Washington University School of Medicine, observed that, obesity has a microbial component, which could be a potential target therapeutic implications [53]. Proceedings of the National Academy of Sciences published an article in 2004, changes in microbial ecology affects predisposition toward energy storage and obesity [54]. Another Study from Academic Medical Center Amsterdam, The Netherlands observed that the alterations in intestinal microbiota are associated with obesity and insulin resistance [55].

4. Impact of gut microbiota on Blood Pressure Regulation:

4.1. The connection between gut bacteria and blood pressure (BP) regulation

The connection between gut bacteria (microbiota) and blood pressure regulation is a relatively new and intriguing area of research. A huge number of studies have suggested that there is a two-way communication between the cardiovascular system and the gut bacteria, including the regulation of blood pressure.

- a. **Short-Chain Fatty Acids (SCFAs):** Short-chain fatty acids (SCFAs) are a class of gut microbial metabolites known to activate multiple signaling pathways in the host. Short-chain fatty acids (SCFAs) are a result of the fermentation of dietary fiber by gut bacteria. Blood vessel relaxation and blood pressure reduction have both been linked to SCFAs. SCFAs enhance the production of nitric oxide that helps dilate blood arteries, boosting blood flow and lowering blood pressure [56].
- b. **Inflammation and Immune Response:** Chronic inflammation as a result of dysbiosis might contribute to the development of hypertension. The immune system's reaction is regulated by the gut microbiota, and inflammation is controlled, both of which have been linked to indirect effects on blood pressure. National Center for Cardiovascular Diseases of China has done a study in 2017 to observe, how Gut microbiota dysbiosis contributes to the development of hypertension [57]. They observed, dysbiosis an important pathogenic factor for the high BP of the host. To further investigate the precise processes underlying the impact of gut microbiome in BP regulation, bacteria including *Prevotella*, *Klebsiella*, *Enterobacter*, and *Fusobacterium* are potential candidates for further bacteria transfer research [58].
- c. **Salt Sensitivity:** According to several research, a person's sensitivity to dietary salt (sodium) may be influenced by the bacteria in their stomach. The development and treatment of hypertension are significantly influenced by salt sensitivity [59].

4.2. Production of nitric oxide by gut bacteria in maintaining healthy blood vessels

Nitric oxide is a biological substance that dilates blood vessels, increases hormone release, modulates neurotransmission, and functions as a signaling molecule. Nitric oxide is produced by both NOS-dependent and -independent pathways [60]. Nitric oxide supplementation improves cardiac health, increases exercise performance, lowers high blood pressure during pregnancy, lowers erectile dysfunction, and improves healing and respiratory responsiveness [61,62]. Here's how the production of nitric oxide by gut bacteria can help maintain healthy blood vessels:

- a. **Dietary Nitrate Conversion:** Dietary nitrate, which is widely found in vegetables such as spinach, beetroot, and lettuce, can be converted into nitrite by particular gut flora. Nitrite can then be further converted into nitric oxide under certain conditions, such as tissue hypoxia. This conversion is mediated by gut enzyme [63–65].
- b. **Influence on Nitric Oxide Synthase (NOS) Activity:** Endothelial nitric oxide synthase (eNOS), an enzyme that generates nitric oxide in blood vessel walls, may be affected by certain gut flora [66]. Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology conduct a study on how Gut Microbiota Homeostasis effects on Nitric Oxide Synthase (NOS) activity. They observed, the concentration NOS in the gastrointestinal tract were increased significantly in shrimp infected with *Vibrio anguillarum*. A gut microbiota dysbiosis situation [67].
- c. **Anti-Inflammatory Effects:** A healthy gut microbiota composition helps to minimize inflammation, which is essential for maintaining healthy blood vessels. Chronic inflammation has been linked to endothelial dysfunction. The inflammatory mediators enter into the bloodstream, through the blood–intestinal barrier which results effects on circulatory system including stiffness of the vessel due to inflammatory reponse. These results increase the blood pressure [68,69]. NO reduced inflammation which indirectly helps blood pressure regulation.

- d. **Gut-Endothelium Axis:** Gut-endothelium axis, or connection between gut microbes and the endothelium, involves a variety of signaling molecules, including those involved in NO generation [70].

5. Diet, Lifestyle, and Gut Health

Intake of nutrients alters the makeup of the gut microbial community and produces metabolites that have an impact on the physiology of the host. Dietary patterns, such as macronutrient balance and feeding/fasting cycles that can be modified with dietary plans based on calorie restriction periods, have an effect on the microbial ecosystem in the gut, which affects homeostasis in that region [71].

- a. **Consumption of Fiber rich diet:** Dietary fiber can have a significant impact on the diversity, richness, and composition of the microbiome by offering a wide range of substrates for fermentation events carried out by particular microbe species that have the enzyme machinery required to break down these complex polysaccharides. [72]. A prebiotic is a compound that feeds the healthy bacteria in the gut, and fiber is one such material. In the process of fermenting dietary fiber, these bacteria create short-chain fatty acids (SCFAs), which have a number of health advantages, including enhancing gut health and lowering inflammation [73].
- b. **Plant-Based vs. Animal-Based Diets:** A plant-based diet rich in vegetables, fruits, whole grains, and nuts promotes a more diversified and healthier gut flora. Animal-based diets, especially those heavy in saturated fats and processed meats, might result in unfavorable alterations in gut microbial composition [74,75].
- c. **Probiotic and Fermented Foods:** Probiotics are advantageous, active bacteria that colonize the human intestines and alter the flora in specific regions of the host. Probiotics may improve or prevent gut inflammation and other intestinal or systemic disease phenotypes by restoring the composition of the gut microbiome and introducing beneficial functionalities to gut microbial communities [76].
- d. **Sugar and Refined Carbohydrates:** Excess sugar consumption has been associated to increased morbidity and mortality and has been connected to the development of numerous illnesses, including metabolic, cardiovascular, neurological, and even some malignancies [77,78]. sugars in the form of nutritious and non-nutritional sweeteners consumption have negative effects on the gut microbial ecosystem, including abnormal short-chain fatty acid synthesis, altered intestinal barrier integrity, and chronic inflammation, which frequently fuels a variety of metabolic conditions [79].
- e. **Mediterranean Diet:** A gut microbiome composition linked to superior health outcomes, including decreased inflammation and improved cardiovascular health, has been found to be connected with the Mediterranean diet, which is high in vegetables, fruits, whole grains, lean proteins, and healthy fats like olive oil [80]. The Mediterranean diet produces gut microbiome regulation in rodents, nonhuman primates, and human subjects, and the potential function of gut microbiota and microbial metabolites as one of the key catalysts mediating the host's many favorable health benefits is discussed [81,82].
- f. **Food Additives:** In today's world, the use of food additives in food manufacturing is unavoidable. Some food additives and emulsifiers included in processed meals have been demonstrated to have a deleterious impact on gut flora and gut barrier integrity [83]. Artificial sweeteners are most likely to damage glucose tolerance and promote weight gain by negatively altering microbiota. The majority of sugar alcohols are fermentable by bacteria and may have qualities comparable to prebiotics[84].

6. Future Implications and Research Directions

There is a clear correlation between gut bacteria and cardiovascular health, according to research. The gut microbiota is involved in various pathways that can affect cardiovascular outcomes, including inflammation, metabolism, and bioactive chemical synthesis. Although much of this research is still in its early phases, manipulating the gut microbiota has emerged as a promising avenue for enhancing cardiovascular health.

- a. **Diet Modification:** Plant-based diets that were processed or ultraprocessed were not connected with healthy clusters of gut bacteria. When selecting foods, think about whether they are processed or unprocessed, as well as if they are plant or animal food. Emphasizing minimally processed plant foods allows the gut microbiome to thrive, providing protection against, or decreasing the risk of, chronic diseases such as heart disease, diabetes, metabolic disease, and obesity. Certain diets, such as those high in fiber and plant-based foods, can help good gut flora proliferate. These bacteria may create short-chain fatty acids (SCFAs), which have anti-inflammatory properties and may benefit cardiovascular health [85].
- b. **Probiotics and Prebiotics:** Several human and animal research have explored the molecular mechanisms underlying the therapeutic benefit of various probiotic and prebiotic substances for gut health. Fibers like inulin and galactomannan have both independent and synergistic health benefits [86].
- c. **Fecal Microbiota Transplantation (FMT):** FMT includes transferring healthy donor feces to a recipient in order to restore a balanced gut flora. The treatment of recurrent *Clostridium difficile* infection with FMT has been proven effective [87]. There are early signs that it may potentially have therapeutic potential for other illnesses such as obesity, metabolic syndrome, inflammatory bowel disease, and functional gastrointestinal disorders [88].
- d. **Stem cell Therapy:** In several disorders, including ulcerative colitis[89], acute liver injury [90], hypoxia-induced pulmonary hypertension, chronic hypoxia, and diabetes [91], which causes gut dysbiosis, researchers have discovered that MSC therapy may be related to the gut microbiota.

7. Conclusion

The gut microbiota is a novel research topic with important applications in human health, particularly in the creation of novel diagnostic and therapeutic techniques for preventative and curative outcomes. Manipulation of gut bacteria via diet, probiotics, and novel approaches may open up new possibilities for enhancing heart health. While the research is still in its early stages, further investigation and collaboration could pave the door for tailored treatments, changing cardiovascular care.

Author Contributions: Conceptualization, S.A. (Shamima Akter), S.T. and M.S.M.; methodology, M.C. and R.B.; software, M.C. and R.B.; validation, S.A. (Shahida Arbee) and M.M.M.; resources, N.M., A.C. and P.S., N.N.B.; writing—original draft preparation; writing—review and editing, M.C., R.B., S.A. (Shahida Arbee) and S.T.; visualization, M.C. and M.M.M.; supervision, M.S.M.; project administration, M.C., N.N.B and M.S.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: The authors want to acknowledge Amayah Mohiuddin, Vardaan Choubey, Lishant Tirumalasetty for their outstanding support.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Structure, function and diversity of the healthy human microbiome. *Nature*. 2012, 486:207-214. doi:10.1038/nature11234
2. Elizabeth Thursby NJ: Introduction to the human gut microbiota. *Biochem J*. 2017. 10.1042/BCJ20160510
3. Analyses of the Stability and Core Taxonomic Memberships of the Human Microbiome | *PLOS ONE*. 2023. 10.1371/journal.pone.0063139

4. Mohammed L, Jha G, Malasevskaia I, Goud HK, Hassan A: The Interplay Between Sugar and Yeast Infections: Do Diabetics Have a Greater Predisposition to Develop Oral and Vulvovaginal Candidiasis? *Cureus*. 2021, 13. 10.7759/cureus.13407
5. Akter S, Choubey M, Arbee S, et al.: Safeguarding Intimate Health: Decoding the Interplay of Diabetes and Erectile Dysfunction. 2023. 10.20944/preprints202308.1440.v1
6. M C, A R, PS B, F B, A K: Direct actions of adiponectin on changes in reproductive, metabolic, and anti-oxidative enzymes status in the testis of adult mice. *General and comparative endocrinology*. 2019, 279. 10.1016/j.ygcen.2018.06.002
7. M C, A R, PS B, A K: Protective role of adiponectin against testicular impairment in high-fat diet/streptozotocin-induced type 2 diabetic mice. *Biochimie*. 2020, 168. 10.1016/j.biochi.2019.10.014
8. M C, A R, A K: Adiponectin/AdipoRs signaling as a key player in testicular aging and associated metabolic disorders. *Vitamins and hormones*. 2021, 115. 10.1016/bs.vh.2020.12.024
9. Growth Hormone and Insulin-like Growth Factor-I: Novel Insights into the Male Reproductive Health. (2023). Accessed: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=oBBDNsAAAAJ&citation_for_view=oBBDNsAAAAJ:ye4kPcJQO24C.
10. MS M, T H, Y Y, et al.: Glucagon Prevents Cytotoxicity Induced by Methylglyoxal in a Rat Neuronal Cell Line Model. *Biomolecules*. 2021, 11. 10.3390/biom11020287
11. B C, O K, JK G, et al.: Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. *Nature*. 2015, 519. 10.1038/nature14232
12. MB A: Could the menagerie of the gut microbiome really cure cancer? Hope or hype. *Journal for immunotherapy of cancer*. 2019, 7. 10.1186/s40425-019-0561-9
13. Ranjan A, Choubey M, Yada T, Krishna A: Immunohistochemical localization and possible functions of nesfatin-1 in the testis of mice during pubertal development and sexual maturation. *Journal of Molecular Histology*. 2019, 50:533-549. doi:10.1007/s10735-019-09846-8
14. A S, M C, P B, A K: Adiponectin and Chemerin: Contrary Adipokines in Regulating Reproduction and Metabolic Disorders. *Reproductive sciences (Thousand Oaks, Calif)*. 2018, 25. 10.1177/1933719118770547
15. Mohib MM, Rabby SMF, Paran TZ, et al.: Protective role of green tea on diabetic nephropathy—A review. <http://www.editorialmanager.com/cogentbio>. 2016. 1248166
16. Mohiuddin MS, Himeno T, Inoue R, et al.: Glucagon-Like Peptide-1 Receptor Agonist Protects Dorsal Root Ganglion Neurons against Oxidative Insult. *J Diabetes Res*. 2019, 2019:9426014. 10.1155/2019/9426014
17. EJ B, SS V, CW C, et al.: Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. *Circulation*. 2018, 137. 10.1161/CIR.0000000000000558
18. SB D, OA K, T B, et al.: Projected Costs of Informal Caregiving for Cardiovascular Disease: 2015 to 2035: A Policy Statement From the American Heart Association. *Circulation*. 2018, 137. 10.1161/CIR.0000000000000570
19. Tasnim Sd, Auny FM, Hassan Y, et al.: Antenatal depression among women with gestational diabetes mellitus: a pilot study. *Reproductive Health*. 2022, 19:1-8. doi:10.1186/s12978-022-01374-1
20. Motegi M, Himeno T, Nakai-Shimoda H, et al.: Deficiency of glucagon gene-derived peptides induces peripheral polyneuropathy in mice. *Biochem Biophys Res Commun*. 2020, 532:47-53. 10.1016/j.bbrc.2020.08.007
21. Munichandrababu T, Bhaskar BV, Ravi S, Bhuvaneswar C, Rajendra W: Structure based virtual screening of non-steroidal anti-inflammatory drugs (NSAIDs) against RNA-binding motif 6 (RBM6) involved in human lung cancer. *Medicinal Chemistry Research*. 2012, 22:2828-2839. doi:10.1007/s00044-012-0276-7
22. RR R, AC M, R K, et al.: Design, synthesis, anticancer, antimicrobial activities and molecular docking studies of theophylline containing acetylenes and theophylline with variant nucleoside derivatives. *European journal of medicinal chemistry*. 2016, 123. 10.1016/j.ejmech.2016.07.024
23. Rajendra W: Anti-Helicobacter pylori and anti-gastric cancer activity of Syzygium alternifolium fruits. <https://www.nutrafoodseu/index.php/nutra>. 2021. <https://www.nutrafoods.eu/index.php/nutra/article/view/77>
24. OC T-C, J M, A G: Colonization and impact of disease and other factors on intestinal microbiota. *Digestive diseases and sciences*. 2007, 52. 10.1007/s10620-006-9285-z
25. MJ C, Department of Microbiology UCC, Ireland., IB J, et al.: Gut microbiota composition correlates with diet and health in the elderly. *Nature*. 2023, 488:178-184. 10.1038/nature11319
26. Akter S, Tasnim Sd, Barua R, et al.: The Effect of COVID-19 on Gut Microbiota: Exploring the Complex Interplay and Implications for Human Health. *Gastrointestinal Disorders*. 2023, 5:340-355. 10.3390/gidisord5030028
27. A F, G I, C M, E C, D S: NFkappaB is a Key Player in the Crosstalk between Inflammation and Cardiovascular Diseases. *International journal of molecular sciences*. 2019, 20. 10.3390/ijms20071599
28. Y F, Y H, Y W, P W, H S, F W: Antibiotics induced intestinal tight junction barrier dysfunction is associated with microbiota dysbiosis, activated NLRP3 inflammasome and autophagy. *PloS one*. 2019, 14. 10.1371/journal.pone.0218384

29. MK P, AL H, PG M: Metabolic endotoxaemia: is it more than just a gut feeling? *Current opinion in lipidology*. 2013, 24. 10.1097/MOL.0b013e32835b4431

30. Gionchetti P, Lammers KM, Rizzello F, Campieri M: Probiotics and barrier function in colitis. 2005. 10.1136/gut.2004.060640

31. CJ W, S K, S D, et al.: Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. *Journal of the American College of Cardiology*. 1999, 34. 10.1016/s0735-1097(99)00448-9

32. Shah PK, Lecis D: Inflammation in atherosclerotic cardiovascular disease. *F1000Research* 2019 8:1402. 2019, 8. doi:10.12688/f1000research.18901.1

33. SM C, PR V: Peripheral Arterial Disease. *Heart, lung & circulation*. 2018, 27. 10.1016/j.hlc.2017.10.014

34. TM B, A R, VB B, S D, D G, W R: Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of *Syzygium alternifolium* through molecular dynamics and pharmacophore-based screening. *Drug design, development and therapy*. 2016, 10. 10.2147/DDDT.S111914

35. G N, G L, RA M, F C: Advances in mechanisms, imaging and management of the unstable plaque. *Atherosclerosis*. 2014, 233. 10.1016/j.atherosclerosis.2014.01.036

36. Galkina E, Ley K: Immune and Inflammatory Mechanisms of Atherosclerosis*. <https://doi.org/10.1146/annurevimmunol021908132620>. 2009. 10.1146/annurev.immunol.021908.132620

37. S Y, S H, S O, et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet (London, England)*. 2004, 364. 10.1016/S0140-6736(04)17018-9

38. J S, ML D, DB G, AR D, P G, JD N: Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. *JAMA*. 2000, 284. 10.1001/jama.284.3.311

39. PW W, RB DA, D L, AM B, H S, WB K: Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998, 97. 10.1161/01.cir.97.18.1837

40. Steinberg D, dsteinberg@ucsd.edu: The LDL modification hypothesis of atherogenesis: an update. *Journal of Lipid Research*. 2009, 50. 10.1194/jlr.R800087-JLR200

41. Bhat BG, b.ganesh.bhat@pfizer.com, Rapp SR, et al.: Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE^{-/-} mice by SC-435. *Journal of Lipid Research*. 2003, 44:1614-1621. 10.1194/jlr.M200469-JLR200

42. The Critical Effect of Bile Acids in Atherosclerosis : *Journal of Cardiovascular Pharmacology*. 2023. 10.1097/FJC.0000000000001320

43. Ridlon JM, Kang, D.J., Hylemon, P.B., Bajaj, J.S.: Bile acids and the gut microbiome. *Current Opinion in Gastroenterology*. 2014. 10.1097/MOG.0000000000000057

44. David LA, Maurice CF, Carmody RN, et al.: Diet rapidly and reproducibly alters the human gut microbiome. *Nature*. 2013, 505:559-563. doi:10.1038/nature12820

45. DJ K, DR P, D S, et al.: Cholesterol Metabolism by Uncultured Human Gut Bacteria Influences Host Cholesterol Level. *Cell host & microbe*. 2020, 28. 10.1016/j.chom.2020.05.013

46. Wang Y, Wang M, Chen J, et al.: The gut microbiota reprograms intestinal lipid metabolism through long noncoding RNA Snhg9. 2023. 10.1126/science.ade0522

47. Haghikia A, Department of Cardiology CUB, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany, German Center for Cardiovascular Research (DZHK) PSB, Berlin, Germany, et al.: Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. *European Heart Journal*. 2023, 43:518-533. 10.1093/eurheartj/ehab644

48. Carbone S, Canada JM, Billingsley HE, Siddiqui MS, Elagizi A, Lavie CJ: Obesity paradox in cardiovascular disease: where do we stand? *Vascular Health and Risk Management*. 2019, 15:89-100. 10.2147/VHRM.S168946

49. TM P-W, P P, LE B, et al.: Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2021, 143. 10.1161/CIR.0000000000000973

50. P P, TD G, GA B, et al.: Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. *Circulation*. 2006, 113. 10.1161/CIRCULATIONAHA.106.171016

51. A K, G S, V M, et al.: Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. *BMC microbiology*. 2017, 17. 10.1186/s12866-017-1027-1

52. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI: An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature*. 2023, 444:1027-1031. doi:10.1038/nature05414

53. Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas M-E: Impact of the gut microbiota on inflammation, obesity, and metabolic disease. *Genome Medicine*. 2016, 8:1-12. doi:10.1186/s13073-016-0303-2

54. F B, H D, T W, et al.: The gut microbiota as an environmental factor that regulates fat storage. *Proceedings of the National Academy of Sciences of the United States of America*. 2004, 101. 10.1073/pnas.0407076101
55. A V, E VN, F H, et al.: Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology*. 2012, 143. 10.1053/j.gastro.2012.06.031
56. Xu J, Moore BN, Pluznick JL: Short-Chain Fatty Acid Receptors and Blood Pressure Regulation: Council on Hypertension Mid-Career Award for Research Excellence 2021. 2022. 10.1161/HYPERTENSIONAHA.122.18558
57. S A, JW N, NJ A, et al.: Alterations in the gut microbiota can elicit hypertension in rats. *Physiological genomics*. 2017, 49. 10.1152/physiolgenomics.00081.2016
58. Li J, Zhao F, Wang Y, et al.: Gut microbiota dysbiosis contributes to the development of hypertension. *Microbiome*. 2017, 5:1-19. doi:10.1186/s40168-016-0222-x
59. Bier A, Braun T, Khasbab R, et al.: A High Salt Diet Modulates the Gut Microbiota and Short Chain Fatty Acids Production in a Salt-Sensitive Hypertension Rat Model. *Nutrients*. 2018, 10:1154. 10.3390/nu10091154
60. Bonetti G, Kiani AK, Medori MC, et al.: Dietary supplements for improving nitric-oxide synthesis. <https://www.jpnh.org/index.php/jpmh>. 2022. <https://www.jpnh.org/index.php/jpmh/article/view/2766>
61. Mark H LH: Acute Effects of an Oral Nitric Oxide Supplement on Blood Pressure, Endothelial Function, and Vascular Compliance in Hypertensive Patients. *J Clin Hypertens*. 2014. 10.1111/jch.12352
62. Najnin RA, Shafrin F, Polash AH, et al.: A diverse community of jute (*Corchorus* spp.) endophytes reveals mutualistic host-microbe interactions. *Annals of Microbiology*. 2014, 65:1615-1626. doi:10.1007/s13213-014-1001-1
63. Leclerc M, Bedu-Ferrari C, Etienne-Mesmin L, et al.: Nitric Oxide Impacts Human Gut Microbiota Diversity and Functionalities. 2021. msystems.00558-21
64. Barua R, Sultana S, Talukder... M: Antioxidant and Cytotoxic Activity of Crude Flavonoid Fraction from the Fruits of Hybrid Variety of *Momordica charantia* (Bitter Gourd). 2014.
65. Babu TMC, Rajesh SS, Bhaskar BV, et al.: Molecular docking, molecular dynamics simulation, biological evaluation and 2D QSAR analysis of flavonoids from *Syzygium alternifolium* as potent anti-*Helicobacter pylori* agents. 2017. 10.1039/C6RA27872H
66. M L, C B-F, L E-M, et al.: Nitric Oxide Impacts Human Gut Microbiota Diversity and Functionalities. *mSystems*. 2021, 6. 10.1128/mSystems.00558-21
67. PP H, XX Z, WJ Y, GJ N, JX W: Nitric Oxide Synthase Regulates Gut Microbiota Homeostasis by ERK-NF- κ B Pathway in Shrimp. *Frontiers in immunology*. 2021, 12. 10.3389/fimmu.2021.778098
68. Battson ML, Lee DM, Jarrell DK, et al.: Suppression of gut dysbiosis reverses Western diet-induced vascular dysfunction. <https://doi.org/10.1152/ajpendo.001872017>. 2018. 10.1152/ajpendo.00187.2017
69. W D, M C, S P, HA S, L O: Adipocyte CAMK2 deficiency improves obesity-associated glucose intolerance. *Molecular metabolism*. 2021, 53. 10.1016/j.molmet.2021.101300
70. van Haver ER, Oste M, Thymann T, et al.: Enteral Feeding Reduces Endothelial Nitric Oxide Synthase in the Caudal Intestinal Microvasculature of Preterm Piglets. *Pediatric Research*. 2023, 63:137-142. doi:10.1203/PDR.0b013e31815f00f9
71. Nova E, Gómez-Martínez S, González-Soltero R: The Influence of Dietary Factors on the Gut Microbiota. *Microorganisms*. 2022, 10:1368. 10.3390/microorganisms10071368
72. Cronin P, Joyce SA, O'Toole PW, O'Connor EM: Dietary Fibre Modulates the Gut Microbiota. *Nutrients*. 2021, 13:1655. 10.3390/nu13051655
73. Fu J, Zheng Y, Gao Y, Xu W: Dietary Fiber Intake and Gut Microbiota in Human Health. *Microorganisms*. 2022, 10:2507. 10.3390/microorganisms10122507
74. Sidhu SRK, Kok CW, Kunasegaran T, Ramadas A: Effect of Plant-Based Diets on Gut Microbiota: A Systematic Review of Interventional Studies. *Nutrients*. 2023, 15:1510. 10.3390/nu15061510
75. Barua R, Mizuno K, Tashima Y, et al.: Bioinformatics and Functional Analyses Implicate Potential Roles for EOGT and L-fringe in Pancreatic Cancers. *Molecules*. 2021, 26:882. 10.3390/molecules26040882
76. Hemarajata P, Versalovic J: Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. <http://dx.doi.org/10.1177/1756283X12459294>. 2012. 10.1177_1756283X12459294
77. Garcia K, Ferreira G, Reis F, Viana S: Impact of Dietary Sugars on Gut Microbiota and Metabolic Health. *Diabetology*. 2022, 3:549-560. 10.3390/diabetology3040042
78. Rashu Barua MEUT, Mohammad Sayedul Islam, Farhana Yesmin, Kanchan Chakma, Md Golam Kabir, Robiul Hasan Bhuiyan: Nutritional Analysis and Phytochemical Evaluation of Bitter Gourd (*Momordica Charantia*) from Bangladesh. 2020. <http://dx.doi.org/10.24203/ajafs.v8i2.6094>
79. J S, T K, D Z, et al.: Artificial sweeteners induce glucose intolerance by altering the gut microbiota. *Nature*. 2014, 514. 10.1038/nature13793
80. J D-L, P P-M, A G-R, et al.: CORonary Diet Intervention with Olive oil and cardiovascular PREvention study (the CORDIOPREV study): Rationale, methods, and baseline characteristics: A clinical trial

- comparing the efficacy of a Mediterranean diet rich in olive oil versus a low-fat diet on cardiovascular disease in coronary patients. *American heart journal*. 2016, 177. 10.1016/j.ahj.2016.04.011
81. Merra G, Noce A, Marrone G, et al.: Influence of Mediterranean Diet on Human Gut Microbiota. *Nutrients*. 2020, 13:7. 10.3390/nu13010007
 82. Md. Ehsan Uddin Talukder FM, Rashu Barua, Samsad Sultana, Farhana Yesmin, Mohammad Sayedul Islam, Robiul Hasan Bhuiyan: In vitro Assessment of Cytotoxic Activity of Hybrid Variety of *Momordica charantia* (Bitter Gourd). 2023. <http://dx.doi.org/10.31254/phyto.2020.9611>
 83. MB A-D, EM E-M, AA A-R, RE M, SS S: Splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats. *Journal of toxicology and environmental health Part A*. 2008, 71. 10.1080/15287390802328630
 84. Campus G, and DI, WHO Collaborating Centre of Milan for Epidemiology and Community Dentistry M, Italy, et al.: Six Months of Daily High-Dose Xylitol in High-Risk Schoolchildren: A Randomized Clinical Trial on Plaque pH and Salivary Mutans Streptococci. *Caries Research*. 2023, 43:455-461. 10.1159/000264682
 85. Singh RK, Chang H-W, Yan D, et al.: Influence of diet on the gut microbiome and implications for human health. *Journal of Translational Medicine*. 2017, 15:1-17. doi:10.1186/s12967-017-1175-y
 86. R F, ER C, A P, F C: Probiotics, prebiotics and synbiotics for weight loss and metabolic syndrome in the microbiome era. *European review for medical and pharmacological sciences*. 2018, 22. 10.26355/eurev_201811_16301
 87. Benech N, Sokol H: Fecal microbiota transplantation in gastrointestinal disorders: time for precision medicine. *Genome Medicine*. 2020, 12:1-4. doi:10.1186/s13073-020-00757-y
 88. Gupta S, Allen-Vercoe E, Petrof EO: Fecal microbiota transplantation: in perspective. <http://dxdoiorg/101177/1756283X15607414>. 2015. 10.1177_1756283X15607414
 89. Soontarak S, Center for Immune and Regenerative Medicine DoCS, College of Veterinary Medicine and Biomedical Sciences Colorado State University, Fort Collins, Colorado, USA, Chow L, et al.: Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse Inflammatory Bowel Disease Model. *Stem Cells Translational Medicine*. 2023, 7:456-467. 10.1002/sctm.17-0305
 90. X D, X F, J L, et al.: Characteristics of Intestinal Microecology during Mesenchymal Stem Cell-Based Therapy for Mouse Acute Liver Injury. *Stem cells international*. 2019, 2019. 10.1155/2019/2403793
 91. Akter S, Choubey M, Mohib MM, Arbee S, Sagor MAT, Mohiuddin MS: Stem Cell Therapy in Diabetic Polyneuropathy: Recent Advancements and Future Directions. *Brain Sciences*. 2023, 13:255. 10.3390/brainsci13020255

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.